Community Investing Ideas

Global Weekly Picks

CA$31.8
FV
98.5% undervalued intrinsic discount
4.4k
users have viewed this narrative
14users have liked this narrative
7users have commented on this narrative
43users have followed this narrative
US$70
62.9% overvalued intrinsic discount
jaikhom's Fair Value
Revenue
-4.25% p.a.
Profit Margin
16.96%
Future PE
227.83x
Price in 2030
US$116.52
US$11.23
62.1% undervalued intrinsic discount
Ontological's Fair Value
Revenue
46.63% p.a.
Profit Margin
22.01%
Future PE
3.48x
Price in 2030
US$15.76
US$95.21
7.0% overvalued intrinsic discount
NVF's Fair Value
Revenue
1.75% p.a.
Profit Margin
7.25%
Future PE
14.5x
Price in 2028
US$120.44
SIP logo
Sipef

Why I Invest in SIPEF?

Strong Operational Momentum Palm oil production up +19.1% YoY , driven by improved yields and extraction rates. Banana volumes up +3.4% , supported by maturing plantations.Read more

View narrative
108
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
€103.79
22.3% undervalued intrinsic discount
fhuyge's Fair Value
Revenue
1% p.a.
Profit Margin
34%
Future PE
9.5x
Price in 2028
€134.41
CA$96.98
31.2% undervalued intrinsic discount
gmalan's Fair Value
Revenue
18.96% p.a.
Profit Margin
20.51%
Future PE
16.63x
Price in 2030
CA$133.9
ITECH logo
I-Tech

I-Tech's Selektope Expansion Will Drive 28% Revenue Increase in 5 Years

Q1 2025 Update Updates to the model and supporting figures below Solid report, above expectation on all lines. Good cashflows, removing doubts/concerns about this topic.Read more

View narrative
281
users have viewed this narrative
2users have liked this narrative
0users have commented on this narrative
27users have followed this narrative
SEK 101.64
49.8% undervalued intrinsic discount
Mandelman's Fair Value
Revenue
19.24% p.a.
Profit Margin
24%
Future PE
18x
Price in 2030
SEK 156.39
ELTX logo
Elicio Therapeutics

Very Bullish

98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more

View narrative
137
users have viewed this narrative
2users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
US$95
91.6% undervalued intrinsic discount
Coward_Nutlick's Fair Value
Profit Margin
21.21%
Future PE
29.38x
Price in 2030
US$0
UK£5
93.3% undervalued intrinsic discount
Double_Bubbler's Fair Value
Revenue
31.98% p.a.
Profit Margin
33%
Future PE
25x
Price in 2030
UK£8.54